• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

Biogen cut at Jefferies as ‘2025 has a tough setup’

by December 9, 2024
written by December 9, 2024

Investing.com — Jefferies downgraded Biogen (NASDAQ:BIIB) from a Buy to Hold on monday, citing a challenging outlook for 2025. 

The firm slashed its price target for the stock to $180 from $250 due to concerns over modest sales growth, a lackluster pipeline, and critical revenue declines looming by 2030.

Analysts highlighted that Biogen’s Alzheimer’s drug, Leqembi, faces slower-than-expected growth, with Jefferies lowering its 2025 sales estimates to $466 million, below the consensus of $494 million. 

“We move to HOLD as 2025 has a tough setup: modest Leqembi (we’re below consensus) and Skyclarys US (mostly penetrated), and real need for more pipeline and serious BD to get investors re-engaged,” said Jefferies.

By 2030, the investment bank projects Leqembi sales at $1.6 billion, significantly under consensus expectations of $4 billion. 

The report stated, “Investors haven’t bought into Leqembi, and we doubt 2025 convinces Street as we remain below.”

Another pressing issue is said to be Biogen’s dependence on royalties from Ocrevus, which currently contributes approximately $1.4 billion annually to its operating income. 

Jefferies warned that this royalty could see a 50% reduction by 2030 due to biosimilar competition, posing a 20-30% hit to Biogen’s earnings power. “This is why they need more pipeline and business development soon to offset $1.5 billion of 2030 loss of Ocrevus,” analysts explained.

Pipeline concerns also weigh on Biogen’s prospects, according to Jefferies. The company has faced multiple pipeline failures in 2024, and key late-stage programs like felzartamab and dapi are not expected to produce results until 2027 or later, leaving little near-term growth potential.

Jefferies suggested Biogen may seek acquisitions in specialty areas like Prader-Willi syndrome or other orphan indications. However, analysts concluded, “2025 has a tough setup,” making immediate recovery unlikely.

 

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Shareholders approve breakup of Bollore’s Vivendi media conglomerate
next post
ByteDance, TikTok seek temporary halt to US ban pending Supreme Court review

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Trump implies government could cut contracts and subsidies to Musk’s companies

      June 7, 2025
    • Procter & Gamble to cut 7,000 jobs as part of broader restructuring

      June 6, 2025
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

      June 6, 2025
    • Shein and Temu see U.S. demand plunge as loophole for cheap goods closes

      June 5, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (505)
    • Stock (6,426)

    Latest News

    • Trump implies government could cut contracts and subsidies to Musk’s companies
    • Procter & Gamble to cut 7,000 jobs as part of broader restructuring

    Popular News

    • ECB starting to debate if rates have to go below neutral, sources say
    • Nvidia’s supply snags hurting deliveries but mask booming demand

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy